Changes in Drug Utilization during a Gap in Insurance Coverage: An Examination of the Medicare Part D Coverage Gap
Background:
Nations are struggling to expand access to essential medications while curbing rising health and drug spending. While the US government's Medicare Part D drug insurance benefit expanded elderly citizens' access to drugs, it also includes a controversial period called the “coverage gap” during which beneficiaries are fully responsible for drug costs. We examined the impact of entering the coverage gap on drug discontinuation, switching to another drug for the same indication, and drug adherence. While increased discontinuation of and adherence to essential medications is a regrettable response, increased switching to less expensive but therapeutically interchangeable medications is a positive response to minimize costs.
Methods and Findings:
We followed 663,850 Medicare beneficiaries enrolled in Part D or retiree drug plans with prescription and health claims in 2006 and/or 2007 to determine who reached the gap spending threshold, n = 217,131 (33%). In multivariate Cox proportional hazards models, we compared drug discontinuation and switching rates in selected drug classes after reaching the threshold between all 1,993 who had no financial assistance during the coverage gap (exposed) versus 9,965 multivariate propensity score-matched comparators with financial assistance (unexposed). Multivariate logistic regressions compared drug adherence (≤80% versus >80% of days covered). Beneficiaries reached the gap spending threshold on average 222 d ±79. At the drug level, exposed beneficiaries were twice as likely to discontinue (hazard ratio [HR] = 2.00, 95% confidence interval [CI] 1.64–2.43) but less likely to switch a drug (HR = 0.60, 0.46–0.78) after reaching the threshold. Gap-exposed beneficiaries were slightly more likely to have reduced adherence (OR = 1.07, 0.98–1.18).
Conclusions:
A lack of financial assistance after reaching the gap spending threshold was associated with a doubling in discontinuing essential medications but not switching drugs in 2006 and 2007. Blunt cost-containment features such as the coverage gap have an adverse impact on drug utilization that may conceivably affect health outcomes.
: Please see later in the article for the Editors' Summary
Vyšlo v časopise:
Changes in Drug Utilization during a Gap in Insurance Coverage: An Examination of the Medicare Part D Coverage Gap. PLoS Med 8(8): e32767. doi:10.1371/journal.pmed.1001075
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1001075
Souhrn
Background:
Nations are struggling to expand access to essential medications while curbing rising health and drug spending. While the US government's Medicare Part D drug insurance benefit expanded elderly citizens' access to drugs, it also includes a controversial period called the “coverage gap” during which beneficiaries are fully responsible for drug costs. We examined the impact of entering the coverage gap on drug discontinuation, switching to another drug for the same indication, and drug adherence. While increased discontinuation of and adherence to essential medications is a regrettable response, increased switching to less expensive but therapeutically interchangeable medications is a positive response to minimize costs.
Methods and Findings:
We followed 663,850 Medicare beneficiaries enrolled in Part D or retiree drug plans with prescription and health claims in 2006 and/or 2007 to determine who reached the gap spending threshold, n = 217,131 (33%). In multivariate Cox proportional hazards models, we compared drug discontinuation and switching rates in selected drug classes after reaching the threshold between all 1,993 who had no financial assistance during the coverage gap (exposed) versus 9,965 multivariate propensity score-matched comparators with financial assistance (unexposed). Multivariate logistic regressions compared drug adherence (≤80% versus >80% of days covered). Beneficiaries reached the gap spending threshold on average 222 d ±79. At the drug level, exposed beneficiaries were twice as likely to discontinue (hazard ratio [HR] = 2.00, 95% confidence interval [CI] 1.64–2.43) but less likely to switch a drug (HR = 0.60, 0.46–0.78) after reaching the threshold. Gap-exposed beneficiaries were slightly more likely to have reduced adherence (OR = 1.07, 0.98–1.18).
Conclusions:
A lack of financial assistance after reaching the gap spending threshold was associated with a doubling in discontinuing essential medications but not switching drugs in 2006 and 2007. Blunt cost-containment features such as the coverage gap have an adverse impact on drug utilization that may conceivably affect health outcomes.
: Please see later in the article for the Editors' Summary
Zdroje
1. LeeYCYangMCHuangYTLiuCHChenSB 2006 Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003. Pharmacoecon 24 891 902
2. SchneeweissSWalkerAMGlynnRJMaclureMDormuthC 2002 Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med 346 822 829
3. PolinskiJMMaclureMMarshallBCasselsAAgnew-BlaisJ 2008 Does knowledge of medication prices predict physicians' support for cost effective prescribing policies. Can J Clin Pharmacol 15 e286 294
4. DormuthCRMaclureMGlynnRJNeumannPBrookhartAM 2008 Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications. Clin Ther 1038 1050 30 Spec No
5. KozyrskyjALMustardCACheangMSSimonsFE 2001 Income-based drug benefit policy: impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma. CMAJ 165 897 902
6. TamblynRLapriseRHanleyJAAbrahamowiczMScottS 2001 Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 285 421 429
7. HuskampHADeverkaPAEpsteinAMEpsteinRSMcGuiganKA 2003 The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 349 2224 2232
8. BirkettDJMitchellASMcManusP 2001 A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Aff 20 104 114
9. SchoffskiO 1996 Consequences of implementing a drug budget for office-based physicians in Germany. Pharmacoecon 10 S37 S47
10. Stewart-BrownSSurenderRBradlowJCoulterADollH 1995 The effects of fund holding in general practice on prescribing habits three years after introduction of the scheme. BMJ 311 1543 1547
11. SoumeraiSBAvornJRoss-DegnanDGortmakerS 1987 Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. N Engl J Med 317 550 556
12. Centers for Medicare and Medicaid Services 2005 Medicare Program; Medicare Prescription Drug Benefit; Final Rule, 42 CFR 70, number 18
13. HoadleyJHargraveECubanskiJNeumanT 2008 The Medicare Part D coverage gap: costs and consequences in 2007 Kaiser Family Foundation Available: http://www.kff.org/medicare/upload/7811.pdf Accessed 31 May 2011
14. PowersC 2008 Beneficiary experience. Part D data symposium. Baltimore (Maryland) Centers for Medicare and Medicaid Services (October 30)
15. FristWH 2005 Shattuck Lecture: health care in the 21st century. N Engl J Med 352 267 272
16. GoldmanDPJoyceGFZhengY 2007 Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 298 61 69
17. HsuJPriceMHuangJBrandRFungV 2006 Unintended consequences of caps on Medicare drug benefits. N Engl J Med 354 2349 2359
18. JoyceGFGoldmanDPKaraca-MandicPZhengY 2007 Pharmacy benefit caps and the chronically ill. Health Aff 26 1333 1344
19. FungVMangioneCMHuangJTurkNQuiterES 2010 Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes. Health Serv Res 45 355 375
20. RaebelMADelateTEllisJLBaylissEA 2008 Effects of reaching the drug benefit threshold on Medicare members' healthcare utilization during the first year of Medicare Part D. Med Care 46 1116 1122
21. SchmittdielJAEttnerSLFungVHuangJTurkN 2009 Medicare Part D coverage gap and diabetes beneficiaries. Am J Manag Care 15 189 193
22. ZhangYDonohueJMNewhouseJPLaveJR 2009 The effects of the coverage gap on drug spending: a closer look at Medicare Part D. Health Aff 28 w317 w325
23. CubanskiJNeumanP 2007 Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage. Health Aff 26 w1 12
24. NesiT 2010 CVS filled 1.3 billion prescriptions in '09. Providence (Rhode Island) Providence Business News
25. RomanoPSRoosLLJollisJG 1993 Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 46 1075 1079; discussion 1081-1090
26. SeegerJDWalkerAMWilliamsPLSaperiaGMSacksFM 2003 A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol 92 1447 1451
27. SteinerJFKoepsellTDFihnSDInuiTS 1988 A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 26 814 823
28. ChoudhryNKShrankWHLevinRLLeeJLJanSA 2009 Measuring concurrent adherence to multiple related medications. Am J Manag Care 15 457 464
29. SchneiderLSTariotPNDagermanKSDavisSMHsiaoJK 2006 Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355 1525 1538
30. RainaPSantaguidaPIsmailaAPattersonCCowanD 2008 Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148 379 397
31. CoxDR 1972 Regression models and life tables (with discussion). J R Stat Soc 34 187 220
32. FineJPGrayRJ 1999 A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 496 509
33. KimHT 2007 Cumulative incidence in competing risks data and competing risks regression analysis. Clin Canc Res 13 559 565
34. FitzmauriceGLairdNWareJ 2004 Applied longitudinal analysis. Hoboken (New Jersey) John Wiley & Sons
35. HeislerMLangaKMEbyELFendrickAMKabetoMU 2004 The health effects of restricting prescription medication use because of cost. Med Care 42 626 634
36. SoumeraiSBRoss-DegnanDAvornJMcLaughlinTChoodnovskiyI 1991 Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med 325 1072 1077
37. SchneeweissSSchoffskiOSelkeGW 1998 What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution? Health Pol 44 253 260
38. TaxisKSchneeweissS 2003 Frequency and predictors of drug therapy interruptions after hospital discharge under physician drug budgets in Germany. Internat J Clin Pharm Ther 41 77 82
39. ShrankWHHoangTEttnerSLGlassmanPANairK 2006 The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 166 332 337
40. SchneeweissSSoumeraiSBGlynnRJMaclureMDormuthC 2002 Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ 166 737 745
41. SchneeweissSDormuthCGrootendorstPSoumeraiSBMaclureM 2004 Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Med Care 42 653 660
42. ChoudhryNKFischerMAAvornJSchneeweissSSolomonDH 2010 At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff 29 1995 2001
43. ChernewMEShahMRWeghARosenbergSNJusterIA 2008 Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff 27 103 112
44. SchneeweissS 2006 Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 15 291 303
45. SuissaS 2008 Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167 492 499
46. HargraveEPiyaBHoadleyJSummerLThompsonJ 2008 Experiences obtaining drugs under Part D: focus groups with beneficiaries, physicians, and pharmacists. Available: http://www.medpac.gov/documents/May08_PartDFocusGroup_CONTRACTOR_JS.pdf. Accessed 10 August 2009
47. CronkAHumphriesTLDelateTClarkDMorrisB 2008 Medication strategies used by Medicare beneficiaries who reach the Part D standard drug-benefit threshold. Am J Health-System Pharm 65 1062 1070
48. HsuJFungVPriceMHuangJBrandR 2008 Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs. JAMA 299 1929 1936
49. HougaardP 1999 Multi-state models: a review. Lifetime Data Analysis 5 239 264
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2011 Číslo 8
- Myasthenia gravis: kombinace chirurgie a farmakoterapie jako nejefektivnější modalita?
- Jak rozpoznat pacienty s familiární hypercholesterolémií ve své praxi
- DESATORO PRE PRAX: Aktuálne odporúčanie ESPEN pre nutričný manažment u pacientov s COVID-19
- Hydroresponzivní krytí v epitelizační fázi hojení rány
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
Najčítanejšie v tomto čísle
- Commercial Serological Tests for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis: An Updated Systematic Review and Meta-Analysis
- Are HIV Epidemics among Men Who Have Sex with Men Emerging in the Middle East and North Africa?: A Systematic Review and Data Synthesis
- Serological Testing Versus Other Strategies for Diagnosis of Active Tuberculosis in India: A Cost-Effectiveness Analysis
- Building the Field of Health Policy and Systems Research: Framing the Questions